Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31693547 | 0.78 | CYP2C19 (0.35) | KMT2A | |
| SCHEMBL23033142 | 0.74 | — | — | |
| SCHEMBL21242582 | 0.74 | — | — | |
| SCHEMBL2520806 | 0.74 | — | — | |
| SCHEMBL9684760 | 0.73 | KMT2A (0.34) | KMT2A | |
| SCHEMBL12162660 | 0.70 | — | — | |
| SCHEMBL23033562 | 0.64 | — | — | |
| SCHEMBL23435178 | 0.64 | KMT2A (0.32) | KMT2A | |
| SCHEMBL938236 | 0.64 | — | — | |
| SCHEMBL238946 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| US-12516039-B2 | N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2025202922-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-02 | — | — | WO | disclosed |
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4236950-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2022093881-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, BRSK2, CLK2 | KMT2A 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.